Broadcom Inc. (NASDAQ:AVGO) is one of the Motley Fool’s high-growth stock picks. On March 23, Broadcom Inc. (NASDAQ:AVGO) unveiled a new cloud-based platform designed to deliver enterprise-grade security to under-resourced SOC teams. Symantec CBX (Carbon Black XDR) is the new platform that combines Symantec and Carbon Black technologies to address industry needs in underserved markets. […]
Broadcom Inc. (NASDAQ:AVGO) is one of the Motley Fool’s high-growth stock picks. On March 23, Broadcom Inc. (NASDAQ:AVGO) unveiled a new cloud-based platform designed to deliver enterprise-grade security to under-resourced SOC teams. Symantec CBX (Carbon Black XDR) is the new platform that combines Symantec and Carbon Black technologies to address industry needs in underserved markets. […]
Amazon.com, Inc. (NASDAQ:AMZN) is one of Motley Fool’s high-growth stock picks. On March 29, Amazon.com, Inc. (NASDAQ:AMZN) cloud unit inked a strategic agreement to become a leading cloud provider of TGS, a provider of energy data and intelligence. The agreement is poised to strengthen ties as TGS has already migrated petabytes of data to the […]
Amazon.com, Inc. (NASDAQ:AMZN) is one of Motley Fool’s high-growth stock picks. On March 29, Amazon.com, Inc. (NASDAQ:AMZN) cloud unit inked a strategic agreement to become a leading cloud provider of TGS, a provider of energy data and intelligence. The agreement is poised to strengthen ties as TGS has already migrated petabytes of data to the […]
NVIDIA Corporation (NASDAQ:NVDA) is one of the Motley Fool’s high-growth stock picks. On March 27, Wolfe Research reiterated an Outperform rating on NVIDIA Corporation (NASDAQ:NVDA) and a $275 price target. The bullish stance affirms the research firm’s confidence in the company’s prospects, driven by the introduction of Rubin Ultra for agentic AI capabilities. During GTC […]
NVIDIA Corporation (NASDAQ:NVDA) is one of the Motley Fool’s high-growth stock picks. On March 27, Wolfe Research reiterated an Outperform rating on NVIDIA Corporation (NASDAQ:NVDA) and a $275 price target. The bullish stance affirms the research firm’s confidence in the company’s prospects, driven by the introduction of Rubin Ultra for agentic AI capabilities. During GTC […]
Apple Inc. (NASDAQ:AAPL) is one of Motley Fool’s high-growth stock picks. On March 26, Apple Inc. (NASDAQ:AAPL) expanded its American Manufacturing Program by adding new partners including Bosch, Cirrus Logic, TDK, and Qnity Electronics. The company plans to invest $400 million through 2030 to strengthen U.S. manufacturing and produce critical components for its products worldwide. […]
Apple Inc. (NASDAQ:AAPL) is one of Motley Fool’s high-growth stock picks. On March 26, Apple Inc. (NASDAQ:AAPL) expanded its American Manufacturing Program by adding new partners including Bosch, Cirrus Logic, TDK, and Qnity Electronics. The company plans to invest $400 million through 2030 to strengthen U.S. manufacturing and produce critical components for its products worldwide. […]
Kalshi Inc. and Polymarket are slinging weighty accusations at each other as the prediction market rivalry heats up and the nascent industry comes under intense scrutiny in Washington. While the platforms have sparred frequently in the past, the rhetoric has escalated in recent days after Kalshi launched a pointed advertising campaign and its employees publicly criticized Polymarket. “Polymarket’s...
Kalshi Inc. and Polymarket are slinging weighty accusations at each other as the prediction market rivalry heats up and the nascent industry comes under intense scrutiny in Washington. While the platforms have sparred frequently in the past, the rhetoric has escalated in recent days after Kalshi launched a pointed advertising campaign and its employees publicly criticized Polymarket. “Polymarket’s irresponsible, dangerous, and illegal behavior threatens legal American prediction markets,” Benjamin Freeman, who works on political and election markets at Kalshi, wrote in a social media post on Monday. The accusations quickly sparked a heated back-and-forth between the companies. “We welcome competition, but believe the discussion should be grounded in facts. Misinforming the public only harms the industry as a whole and participants,” Polymarket said in a statement. Elisabeth Diana, a spokesperson for Kalshi, responded: “That’s laughable, coming from a company whose majority of trading volume is offshore and unregulated, and whose policies allow death markets.” The feuding comes as Polymarket and Kalshi battle for leadership of the fast-growing prediction market industry, which has opened up a new way for Americans to wager on everything from sports to elections. The startups have both registered one record trading week after another, with nearly $6 billion in notional trading volume between them in recent weeks, according to user-compiled data on Dune Analytics. Differences in how the exchanges are set up and operate are at the heart of the dispute. Kalshi’s platform is based in the US and overseen by the Commodity Futures Trading Commission, while Polymarket’s primary exchange operates offshore. Polymarket has used its operations outside the US to list contracts tied to military conflict — including the war in Iran — which Kalshi has said are unethical and illegal. “We don’t do death markets,” one of Kalshi’s ads reads. Read More: Iran Strikes Expose Dark Edge Case ...
Taitai6769/iStock via Getty Images Nucor ( NUE ) and Commercial Metals ( CMC ) both rise 2.7% in Wednesday's trading as Goldman Sachs started coverage with Buy ratings and respective $210 and $74 price targets, expecting U.S. steel shipments to rise as a result of declining imports due to tariffs, as U.S. producers increase volumes to compensate for the lack of international steel imports. The ban...
Taitai6769/iStock via Getty Images Nucor ( NUE ) and Commercial Metals ( CMC ) both rise 2.7% in Wednesday's trading as Goldman Sachs started coverage with Buy ratings and respective $210 and $74 price targets, expecting U.S. steel shipments to rise as a result of declining imports due to tariffs, as U.S. producers increase volumes to compensate for the lack of international steel imports. The bank said it expects U.S. steel shipment growth will outpace demand growth in 2026, while volume growth for domestic shipments is still greater than import volume growth in 2027 before moderating in 2028. The current steel price environment should act as a tailwind for all producers with metal price exposure, but given the recent pullback as a result of inflation and global growth fears, Goldman's Nick Cash and Cecilia Tang see current prices providing an attractive entry point for select U.S. steel equities, particularly Nucor ( NUE ) and Commercial Metals ( CMC ). Goldman's Buy rating on Nucor ( NUE ) is supported by three key factors: the company is poised to outperform the U.S. steel market through rising end-market demand, import share gains, and growth-related volume expansion via its West Virginia mill; structural cost advantages that should drive margin expansion; and a transition from heavy capital investment to a free cash flow harvesting phase. Cash and Tang said Commercial Metals ( CMC ) is a Buy because of strong North America end-market demand with exposure to U.S. regions with above-average growth; inorganic and organic margin expansion and growth position the company well ahead of the cycle; and a strategic focus on prioritizing balance sheet health and cash flow generation over immediate capital returns. The analysts took a Neutral view on Cleveland-Cliffs ( CLF ), citing caution on the high fixed cost structure of the business as steel prices likely have posted near-term highs. More on Nucor and Commercial Metals Nucor: Tariff Turmoil Is Why You Stick With Hi...
Sandhya Venkatachalam, founder of Axiom Partners, joins Dani Burger on "Bloomberg Deals." They discuss how venture capital is addressing the rising valuations tied to AI businesses. (Source: Bloomberg)
Sandhya Venkatachalam, founder of Axiom Partners, joins Dani Burger on "Bloomberg Deals." They discuss how venture capital is addressing the rising valuations tied to AI businesses. (Source: Bloomberg)
quantic69/iStock via Getty Images The last time I wrote about United Therapeutics Corporation ( UTHR ) it was in a Seeking Alpha article entitled " United Therapeutics: Nebulized Tyvaso Label Expansion Possible For IPF After Study Win ." With respect to this article, I mentioned that the company was able to achieve positive results from its phase 3 TETON-2 study using nebulized Tyvaso for the trea...
quantic69/iStock via Getty Images The last time I wrote about United Therapeutics Corporation ( UTHR ) it was in a Seeking Alpha article entitled " United Therapeutics: Nebulized Tyvaso Label Expansion Possible For IPF After Study Win ." With respect to this article, I mentioned that the company was able to achieve positive results from its phase 3 TETON-2 study using nebulized Tyvaso for the treatment of patients with idiopathic pulmonary fibrosis [IPF]. Specifically, the primary endpoint of change in absolute Forced Vital Capacity [FVC] from baseline to week 52 was met in favor of Tyvaso in a statistically significant manner. I had a Strong Buy rating, and today I'm going to stick to it because of what just happened. The company was able to achieve another win with respect to the development of this IPF treatment program. A few days ago on March 30, 2026, it noted that it had also achieved positive results from its phase 3 TETON-1 study using Tyvaso to treat patients with IPF. What makes this study a huge win compared to the last one is that there was an even better effect on improving absolute [FVC] in this trial. Plus, this study was the one that recruited patients from the United States and Canada. Why the continued Strong Buy rating? That's because now this company has positive data from both TETON-1 and TETON-2 to seek supplemental New Drug Application [sNDA] approval of Tyvaso for the treatment of patients with IPF. Speaking of which, as an update, it believes it is on track to submit such a regulatory application for approval of this IPF indication by the end of this summer. Even better, it is going to seek Priority Review as well, which could speed up the review time. Lastly, the company is already in the process of an expansion opportunity. It is also currently evaluating the use of Tyvaso in the ongoing phase 3 TETON-PPF for the treatment of patients with progressive pulmonary fibrosis [PPF]. With its second phase 3 study win of Tyvaso for the treatment ...
Former FTX engineering chief Nishad Singh will have to return $3.7 million in illegal profits under a settlement with the US derivatives regulator over his role at the collapsed cryptocurrency exchange. Singh will also be banned from trading for five years and prohibited from registering with the regulator for eight years, the Commodity Futures Trading Commission said in a statement on Wednesday. ...
Former FTX engineering chief Nishad Singh will have to return $3.7 million in illegal profits under a settlement with the US derivatives regulator over his role at the collapsed cryptocurrency exchange. Singh will also be banned from trading for five years and prohibited from registering with the regulator for eight years, the Commodity Futures Trading Commission said in a statement on Wednesday. The agency said it didn’t seek a monetary penalty or restitution based on his cooperation in the investigation. “The injunctions and monetary relief imposed here demonstrate the significant benefits that may be achieved through cooperating with the CFTC,” Enforcement Director David Miller said. A spokesperson for Singh didn’t immediately respond to a request for comment. The former FTX engineering chief pleaded guilty to fraud in 2023 as part of a deal with federal prosecutors and later avoided prison time . He was one of the top executives who testified against Sam Bankman-Fried , the co-founder of the once high-flying crypto exchange that imploded in 2022. Bankman-Fried is currently serving a 25-year prison sentence. He filed a long-shot request earlier this year for a new trial.
sankai/iStock via Getty Images Individual investors’ allocations to cash increased while stock and bond allocations decreased in the March AAII Asset Allocation Survey. Stock and stock fund allocations decreased 0.2 percentage points to 69.2%. Stock and stock fund allocations are above their historical average of 61.5% for the 70th consecutive month. Bond and bond fund allocations decreased 0.6 pe...
sankai/iStock via Getty Images Individual investors’ allocations to cash increased while stock and bond allocations decreased in the March AAII Asset Allocation Survey. Stock and stock fund allocations decreased 0.2 percentage points to 69.2%. Stock and stock fund allocations are above their historical average of 61.5% for the 70th consecutive month. Bond and bond fund allocations decreased 0.6 percentage points to 15.8%. Bond and bond fund allocations are below their historical average of 16.0% for the fifth time in six months. Cash allocations increased 0.8 percentage points to 15.0%. Cash allocations are below their historical average of 22.5% for the 40th consecutive month. March AAII Asset Allocation Survey results: Stocks and Stock Funds: 69.2%, down 0.2 percentage points Bonds and Bond Funds: 15.8%, down 0.6 percentage points Cash: 15.0%, up 0.8 percentage points March AAII Asset Allocation Survey details: Stocks: 29.5%, down 1.3 percentage points Stock Funds: 39.7%, up 1.0 percentage points Bonds: 5.1%, down 0.1 percentage points Bond Funds: 10.7%, down 0.5 percentage points Historical averages: Stocks/Stock Funds: 61.5% Bonds/Bond Funds: 16.0% Cash: 22.5% The AAII Asset Allocation Survey has been conducted monthly since November 1987 and asks AAII members what percentage of their portfolios are allocated to stocks, stock funds, bonds, bond funds and cash.
A lot of people look forward to turning 65 because that's when Medicare eligibility generally starts. But it's not a given that you'll want to enroll in Medicare at age 65. It may be that you're still working at 65 or have health insurance through a spouse's workplace plan. At that point, why enroll in Medicare -- and pay for it -- when you're happy with your coverage? Image source: Getty Images. ...
A lot of people look forward to turning 65 because that's when Medicare eligibility generally starts. But it's not a given that you'll want to enroll in Medicare at age 65. It may be that you're still working at 65 or have health insurance through a spouse's workplace plan. At that point, why enroll in Medicare -- and pay for it -- when you're happy with your coverage? Image source: Getty Images. Continue reading
Marvell Technology (NASDAQ:MRVL) shares are up 7% in Wednesday trading, climbing above $106 after opening at $99.05. The catalyst is unmistakable: NVIDIA‘s (NASDAQ:NVDA) $2 billion strategic investment in Marvell, integrating the company into the NVIDIA AI factory and AI-RAN ecosystem through NVLink Fusion. The move puts Marvell squarely at the center of the AI infrastructure ... Marvell Technolog...
Marvell Technology (NASDAQ:MRVL) shares are up 7% in Wednesday trading, climbing above $106 after opening at $99.05. The catalyst is unmistakable: NVIDIA‘s (NASDAQ:NVDA) $2 billion strategic investment in Marvell, integrating the company into the NVIDIA AI factory and AI-RAN ecosystem through NVLink Fusion. The move puts Marvell squarely at the center of the AI infrastructure ... Marvell Technology Rises 7%: The NVIDIA NVLink Deal Is Turning This Chip Stock Into an AI Powerhouse